China’s Butylphthalide market – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:31 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg China’s Butylphthalide market – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Butylphthalide Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-butylphthalide-market-2021-2025/ Thu, 27 May 2021 06:56:09 +0000 https://www.cri-report.com/?post_type=product&p=11653 CRI predicts that as the price of Butylphthalide will decrease, the sales volume of Butylphthalide will keep a rising trend from 2021 to 2025.

The post Investigation Report on China’s Butylphthalide Market 2021-2025 first appeared on CRI Report.

]]> Description
Butylphthalide, developed by CSPC Enbipu Pharmaceutical Co. Ltd is used to treat mild to moderate acute ischemic stroke. Its soft capsule was approved in China in 2005, and its injection was approved in China in 2010. In 2009, Butylphthalide soft capsules were included in the Medicines List for National Basic Medical Insurance in China. In 2017, Butylphthalide injection was included in the Medicines List for National Basic Medical Insurance in China. By 2020, the only manufacturers are CSPC Enbipu Pharmaceutical Co. Ltd. in the Chinese Butylphthalide market.

According to CRI analysis, the sales of Butylphthalide have grown from 2016 to 2020. Especially, the annual growth rate is more than 30%, after the price cut through negotiations in 2019. Its sales have increased the most obviously, from CNY1.22 billion in 2018 to CNY 1.59 billion in 2019. The CAGR of the sales of Butylphthalide in the Chinese market from 2016 to 2020 is 14.7%.

CRI predicts that as the price of Butylphthalide will decrease, the sales volume of Butylphthalide will keep a rising trend from 2021 to 2025. Butylphthalide was once again listed as a drug for medical insurance price negotiations in 2020. It can be expected that the price will drop by about 50% after the negotiation is successful, which will lead to an increase in sales as the price drops. Moreover, Butylphthalide injections and patented capsules will expire in 2022 and 2023 respectively. After the patent expires, many companies will participate in the market competition. The price will drop with the addition of new manufacturers. The sales volume and sales will grow accordingly. Furthermore, with the increase of population aging, the incidence of some diseases continues to rise, prompting the demand for Butylphthalide in the Chinese market.

Topics Covered:
-The impact of COVID-19 on China’s Butylphthalide market
– Sales value of China’s Butylphthalide 2016-2020
– Competitive landscape of China’s Butylphthalide market
– Prices of Butylphthalide in China
– Prices of Butylphthalide in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Butylphthalide market
– Prospect of China’s Butylphthalide market from 2021 to 2025

The post Investigation Report on China’s Butylphthalide Market 2021-2025 first appeared on CRI Report.

]]>